A
Here's one that mentions being mutation-specific (also from CFF website)...
VX-770 (Vertex Pharmaceuticals) - VX-770 is a new compound called a "potentiator" that may act upon the CFTR protein and help to open the chloride channel in CF cells. Phase 1 dosing has been completed in patients. Researchers are evaluating results and a Phase 2 trial has begun in CF patients.
The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
Here's one that mentions being mutation-specific (also from CFF website)...
VX-770 (Vertex Pharmaceuticals) - VX-770 is a new compound called a "potentiator" that may act upon the CFTR protein and help to open the chloride channel in CF cells. Phase 1 dosing has been completed in patients. Researchers are evaluating results and a Phase 2 trial has begun in CF patients.
The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.